Novel immunosuppressants in asthma.
Kon
O M
OM
Chest and Allergy Clinic, St Mary's Hospital, London, UK. onn.kon@sm.stmarys-tr.nthames.nhs.uk
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D015704:CD4 Antigens / Q000276:immunology; D018592:Cross-Over Studies; D016572:Cyclosporine / Q000627:therapeutic use; D004311:Double-Blind Method; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008727:Methotrexate / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D018448:Models, Immunological; D050607:Organogold Compounds; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D015704:CD4 Antigens; D007166:Immunosuppressive Agents; D050607:Organogold Compounds; D016572:Cyclosporine; D020123:Sirolimus; D016559:Tacrolimus; D008727:Methotrexate